Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

This study has been completed.
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Cavion LLC
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01480050
First received: November 23, 2011
Last updated: December 22, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)